More than 65% of MSME firms have been found to be manufacturing drugs that are not of standard quality (NSQ), during risk-based inspections of pharma companies conducted since December last year, said a person with knowledge of the matter.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u6NTIyi
via IFTTT
No comments:
Post a Comment